Clinical Trial Detail

NCT ID NCT02036086
Title Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Sunnybrook Health Sciences Centre
Indications

melanoma

Therapies

Cobimetinib + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST